Study of Nitric Oxide in Patients with Chronic Hepatitis C Genotype 4: Relationship to Viremia and Response to Antiviral Therapy

REFERENCES

• Aljumah, F., Kanawi, R. Al., Alahdal, A. O., Mayet, A. H., Al-Karawi, A. J., Sbeih, G. (2000). Treatment of chronic hepatitis C genotype IV with interferon–ribavirin combination in Saudi Arabia: a multicentre study. J. Viral Hep. 7(4):287–291.
   PubMed Web of Science ®Google Scholar
• Amaro, M. J., Bartolome, J., Pardo, M., Cotonat, T., Lopez-Farre, A., Carreno, V. (1997). Decreased nitric oxide production in chronic viral hepatitis B and C. J. Med. Virol. 51:326–31.
   PubMed Web of Science ®Google Scholar
• Carreño, V. (2006). Occult hepatitis C virus infection: A new form of hepatitis C. World J. Gastroenterol. 21;12(43):6922–6925.
   PubMed Web of Science ®Google Scholar
• Corghi, D. B., Gonçales, N. S., Marques, S. B., Gonçales, Jr. F.L. (2008). Distribution of the human leucocyte antigen class II alleles in Brazilian patients with chronic hepatitis C virus infection. Braz J Med Biol Res. 41(10):884–889.
   PubMed Web of Science ®Google Scholar
• Cramp, M. E., Rossol, S., Chokshi, S., Carucci, P., Williams, R., Naoumov, N. V. (2000). Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology 118:346–355.
   PubMed Web of Science ®Google Scholar
• Degroote, M. A., Fang, F. C. (1995). NO inhibitions. Antimicrobial properties of nitric oxide. Clin. Infect. Dis. 21:S162–S165.
   PubMed Web of Science ®Google Scholar
• Devin, J. K., Vaughan, D. E., Blevins, L.S. Jr., Chen, Q., Covington, J., Verity, D. K., Young, P. P. (2008). Low-dose growth hormone administration mobilizes endothelial progenitor cells in healthy adults. Growth Horm IGF Res. 18(3):253–263.
   PubMed Web of Science ®Google Scholar
• Dustin, L. B., Rice, C. M. (2007). Flying under the radar: the immunobiology of hepatitis C. Annu. Rev. Immunol. 25:71–99.
   PubMed Web of Science ®Google Scholar
• el-Zayadi, A., Simmonds, P., Dabbous, H., Prescott, L., Selim, O., Ahdy, A. (1996). Response to interferon-alpha of Egyptian patients infected with hepatitis C virus genotype 4. J, Viral. Hepat. 3:261–264.
   PubMed Web of Science ®Google Scholar
• Hokaria, A., Zeniya, M., Esumib, H., Ishikawaa, T., Kurasimab, Y., Toda, G. (2005). Role of nitric oxide (NO) in interferon-alpha therapy for hepatitis C. J. Infect. 51:47–53.
   PubMed Web of Science ®Google Scholar
• Kanai, K., Kako, M., Okamoto, H. (1992). HCV genotypes in chronic hepatitis C and response to interferon. Lancet 339:1543.
   PubMed Web of Science ®Google Scholar
• Lai, M. M. (2002). Hepatitis C virus proteins: direct link to hepatic oxidative stress, steatosis, carcinogenesis and more. Gastroenterology 122:568–571.
   PubMed Web of Science ®Google Scholar
• Large, M. K., Kittlesen, D. J., Hahn, Y. S. (1999). Suppression of host immune response by the core protein of hepatitis C virus: possible implications for hepatitis C virus persistence. J. Immunol. 162:931–938.
   PubMed Web of Science ®Google Scholar
• Lee, C. H., Choi, Y. H., Yang, S. H., Lee, C. W., Ha, S. J., Sung, Y.C. (2001). Hepatitis C virus core protein inhibits interleukin 12 and nitric oxide production from activated macrophages. Virology 279:271–279.
   PubMed Web of Science ®Google Scholar
• Lluch, P., Cortina, B., Vila, J. M., Segarra, G., Mauricio, M. D., del Olmo, J. A., Serra, M. A., Lluch, S., Rodrigo, J. M. (2009). Unchanged plasma levels of dimethylarginines and nitric oxide in chronic hepatitis C. Scand. J. Gastroenterol. 4, 224–228.
   Google Scholar
• Lyra, A. C., Ramrakhiani, S., Bacon, B. R., Di Bisceglie, A. M. (2004). Infection with hepatitis C virus genotype 4 in the United States. J. Clin. Gastroenterol. 38:68–71.
   PubMed Web of Science ®Google Scholar
• McHutchison, J. G., Gordon, S. C., Schiff, E. R., Shiffman, M. L., Lee, W. M., Rustgi, V. K., Goodman, Z. D., Ling, M. H., Cort, S., Albrecht, J. K. (1998). Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med. 19; 339(21):1485–1492.
   Google Scholar
• Machida, K., Cheng, K. T., Sung, V. M., Lee, K. J., Levine, A. M., Lai, M. M. (2004). Hepatitis C virus infection activates the immunologic (Type II) isoform of nitric oxide synthase and thereby enhances DNA damage and mutations of cellular genes. Virology 78(16): 8835–8843.
   Web of Science ®Google Scholar
• Machida, K., Cheng, K. T., Sung, V. M., Shimodaira, S., Lindsay, K. L., Levine, A. M., Lai, M. Y., Lai, M. M. (2004). Hepatitis C virus induces a mutator phenotype. Proc. Natl. Acad. Sci. USA 101:4262–4267.
   PubMed Web of Science ®Google Scholar
• Mihm, S., Fayyazi, A., Ramadori, G. (1997). Hepatic expression of inducible nitric oxide synthase transcripts in chronic hepatitis C virus infection: Relation to hepatic viral load and liver injury. Hepatology 26(2):451–458.
   PubMed Web of Science ®Google Scholar
• Nathan, C., Xie, Q.-W. (1994). Regulation of biosynthesis of nitric oxide. J. Biol. Chem. 269:13725–13728.
   PubMed Web of Science ®Google Scholar
• Neuman, M. G., Sha, K., Esguerra, R., Zakhari, S., Winkler, R. E., Hilzenrat, N., Wyse, J., Cooper CL, Seth D, Gorrell MD, Haber PS, McCaughan GW, Leo MA, Lieber CS, Voiculescu M., Buzatu, E., Ionescu, C., Dudas, J., Saile, B., Ramadori, G. (2008). Inflammation and repair in viral hepatitis C. Dig. Dis. Sci. 53(6):1468–1487.
   PubMed Web of Science ®Google Scholar
• Ning, Q., Brown, D., Parodo, J., Cattral, M., Gorczynski, R., Cole, E., Fung, L., Ding, J.W., Liu, M. F., Rotstein, O., Phillips, M. J., Levy, G. (1998). Ribavirin inhibits viral induced macrophage production of TNF, IL-1, the procoagulant fgl2 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response. J. Immunol. 160:3487–3493.
   PubMed Web of Science ®Google Scholar
• Poynard, T., Marcellin, P., Lee, S. S., Niederau, C., Minuk, G. S., Ideo, G., Bain, V., Heathcote, J., Zeuzem, S., Trepo, C., Albrecht, J. (1998). Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT) Lancet 352(9138):1426–1432.
   PubMed Web of Science ®Google Scholar
• Ohno, O., Mizokami, M., Wu, R. R., Saleh, M. G., Ohba, K., Orito, E., Mukaide, M., Williams, R., Lau, J. Y. (1997). New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. J. Clin. Microbiol. 35(1):201–207.
   PubMed Web of Science ®Google Scholar
• Okuda, M., Li, K., Beard, M.R., Showalter, L.A., Scholle, F., Lemon, S. M., Weinman, S. A. (2002). Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 122:366–375.
   PubMed Web of Science ®Google Scholar
• Okuda, M., Li, K., Beard, M. R., Showalter, L. A., Scholle, F., Lemon, S. M., Weinman, S. A. (2002). Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 122:366–375.
   PubMed Web of Science ®Google Scholar
• Osman, H. G., Gabr, O. M., Lotfy, S., Gabr, S. (2007). Serum levels of bcl-2 and cellular oxidative stress in patients with viral hepatitis. Ind. J. Med. Microbiol. 25(4):323–329.
   PubMedGoogle Scholar
• Samuel, C. E. (2001). Antiviral actions of interferons. Clin. Microbiol. Rev. 14(4): 778–809.
   PubMed Web of Science ®Google Scholar
• Sharara, A. I., Perkins, D. J., Misukonis, M. A., Chan, S. U., Dominitz, J. A., Weinberg, J. B. (1997). Interferon (IFN)-alpha activation of human blood mononuclear cells in vitro and in vivo for nitric oxide synthase (NOS) type 2 mRNA and protein expression: possible relationship of induced NOS2 to the anti-hepatitis C effects of IFN-alpha in vivo. J. Exp. Med. 186:1495–1502.
   PubMed Web of Science ®Google Scholar
• Shobokshi, O., Serebour, F. R., Skakni, L., Al Jaser, N., Tantawe, A. O., Sabah, A., Dinish, T., Qatani, T., Sandokji, A., Al-Blowi, A., Karawi, M., Al-Kayyal, B., Al-Momen, S., Akbar, H., Ayoola, A., El-Hazmi, M., El-Hazmi, M., Humaida, A., Eissa, H., Al-Quaiz, M., Khawajah, F., Al-Khalifa, M. (2002). Peg-IFN Alfa-2a (40kda) As a monotherapy or in combination with ribavirin significantly improve end of treatment response rate. In: HCV Genotype 4 Chronic Active Hepatitis (CAH) Patients. 53rd AASLD 2002. Boston, MA. Hepatology 36:2.
   Google Scholar
• Tanaka, Y., Nishida, N., Sugiyama, M., Kurosaki, M., Matsuura, K., Sakamoto, N., (2009). Genome-wide association of IL28B with response to pegylated interferon-│[alpha]│ and ribavirin therapy for chronic hepatitis C. Nature Genetics 41: 1105–1109.
   PubMed Web of Science ®Google Scholar
• Tanaka, Y., Agha, S., Saudy, N., Kurbanov, F., Orito, E., Kato, T., Abo-Zeid, M., Khalaf, M., Miyakawa, Y., Mizokami, M. (2004). Exponential spread of hepatitis C virus genotype 4a in Egypt. J. Mol. Evol. 58(2):191–195.
   PubMed Web of Science ®Google Scholar
• Taylor-Robinson, A. W., Liew, F. Y., Severn, A., Xu, D., McSorley, S. J., Garside, P., Padron, J., Phillips, R. S. (1994). Regulation of the immune response by nitric oxide differentially produced by T helper type 1 and T helper type 2 cells. Eur. J. Immunol. 24:980–984.
   PubMed Web of Science ®Google Scholar
• Thurairajah, P. H., Thorburn, D., Hubscher, S., White, A., Lai, W. K., O'Donnell, K., Mutimer, D. (2007). Incidence and characterization of serum transaminases elevations in pegylated interferon and ribavirin treated patients with chronic hepatitis C. Aliment Pharmacol Ther. 25(11):1293–1300.
   PubMed Web of Science ®Google Scholar
• Yee, L. J., Im, K., Wahed, A. S., Bugawan, T., Li, J., Rhodes, S. L., Erlich, H., Rosen, H. R., Liang, T. J., Yang, H. (2009). Polymorphism in the human major histocompatibility complex and early viral decline during treatment of chronic hepatitis C. Antimicrob. Agents Chemother. 53(2):615–621.
   PubMed Web of Science ®Google Scholar